Type 2 diabetes in latin America: recommendations on the flash glucose monitoring system

Vista sencilla de ítem
dc.contributor.authorKrakauer, Marcio
dc.contributor.authorGómez, Ana M.
dc.contributor.authorAlmeda-Valdes, Paloma
dc.contributor.authorManrique, Helard
dc.contributor.authorRuiz Morosini, María Lidia
dc.contributor.authorGodoy Jorquera, Gonzalo
dc.contributor.authorNunes Salles, João Eduardo
dc.contributor.authorSanhueza Costa, David
dc.contributor.authorde Azeredo Siqueira, Rodrigo
dc.contributor.authorFaradji, Raquel N.
dc.contributor.authorRincón Ramírez, Alex
dc.contributor.authorRé, Matías
dc.date.accessioned2025-04-23T15:08:26Z
dc.date.available2025-04-23T15:08:26Z
dc.date.issued2024-12
dc.descriptionIndexación (Scopus)
dc.description.abstractObjective: To establish recommendations through the consensus of a Latin American experts panel on the use of the flash glucose monitoring system (fCGM) in people living with type 2 diabetes mellitus (T2DM) regarding the benefits and challenges of using the fCGM. Methods: An executive committee of experts was created, comprised by a panel of fifteen physicians, including endocrinologists and internal medicine physicians, with expertise in management of adult patients with T2DM. The experts were from various countries: Colombia, Chile, Peru, Mexico, Argentina, and Brazil. The modified Delphi method was used, considering a consensus level of at least 80% of the participants. A seventeen-item instrument was developed to establish recommendations on the use of fCGM in patients with T2DM in Latin American. Results: The number of glucose scans recommended per day with the fCGM for patients managed with oral antidiabetic drugs or basal insulin was a median of 6 scans per day, and for those managed with multiple insulin doses, a median of 10 scans per day was recommended. Additionally, a holistic and individualized management approach was recommended, taking into account new treatment directions and identifying patients who would benefit from the use of the fCGM. Conclusion: Continuous use of the fCGM is recommended for people living with T2DM, regardless of their type of treatment. These metrics must be evaluated individually for each patient profile.
dc.description.urihttps://link.springer.com/article/10.1186/s13098-024-01343-7?utm_source=getftr&utm_medium=getftr&utm_campaign=getftr_pilot&getft_integrator=scopus
dc.identifier.citationDiabetology and Metabolic Syndrome Volume 16, Issue 1 December 2024 Article number 106
dc.identifier.doi10.1186/s13098-024-01343-7
dc.identifier.issn1758-5996
dc.identifier.urihttps://repositorio.unab.cl/handle/ria/64257
dc.language.isoen_US
dc.publisherDiabetology and Metabolic Syndrome Open AccessVolume 16, Issue 1December 2024 Article number 106
dc.rights.licenseAtribución/Reconocimiento 4.0 Internacional
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.es
dc.subjectConsensus
dc.subjectFlash Continuous Glucose Monitoring System
dc.subjectType 2 Diabetes
dc.titleType 2 diabetes in latin America: recommendations on the flash glucose monitoring system
dc.typeArtículo
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Type-2-diabetes-in-latin-America-recommendations-on-the-flash-glucose-monitoring-systemDiabetology-and-Metabolic-Syndrome.pdf
Tamaño:
865.87 KB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FM - Artículos de Revista